SynthesisMolecular biotechnology2024
A Systematic Review of the Potential of Pichia pastoris (Komagataella phaffii) as an Alternative Host for Biologics Production.
Synthesis in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Development and characterization of a Cre/Synthetic and systems biotechnology · 2027Article
- Advances in Key Genetic Elements and Strategies for High-Yield Heterologous Protein Expression inJournal of fungi (Basel, Switzerland) · 2026Review
- Heterologous Systems in the Functional Characterization of Proteins from Phytopathogenic Fungi: A Systematic Review.Molecular biotechnology · 2026Article
- Article
- Tri-valorization of methanol in a single bioreactor: co-production of enzyme, chemical, and single-cell protein using engineered Pichia pastoris (Komagataella phaffii).Bioresources and bioprocessing · 2026Article
- Development and optimization of a glycerol-based fed-batch strategy for the production of peroxidases with Komagataella phaffii under the PMicrobial cell factories · 2026Article
- The transcriptional response to environmental alkalization involves both Komagataella phaffii Pho4 transcription factors.Microbial cell factories · 2026Article
- FormatotrophicSynthetic and systems biotechnology · 2026Article
- Expression and identification of a novel high-activity recombinant humanized type I collagen SynthCol1 in Pichia pastoris GS115.Applied microbiology and biotechnology · 2026Article
- Molecular engineering of Komagataella phaffii for venom toxin production.Applied microbiology and biotechnology · 2026Review
- Characterizing the role of an endogenous serine protease KpSub2 in recombinant collagen degradation in Komagataella phaffii.Bioresources and bioprocessing · 2026Article
- A fast workflow to explore active enzymes from environmental samples through functional metagenomics.Applied microbiology and biotechnology · 2026Article
- Expression of a recombinant lactoferrin N-terminal functional fragment in three expression systems and its efficacy against enterotoxigenic Escherichia coli K88 infection.BMC veterinary research · 2026Article
- Multistep metabolic engineering of Pichia pastoris for biosynthesis of N‑acetylneuraminic acid.Applied microbiology and biotechnology · 2026Article
- Boosting Recombinant Bovine Chymosin inFoods (Basel, Switzerland) · 2026Article
- Development and Application of a Cumate-Inducible Promoter, PMicrobial biotechnology · 2026Article
- Progress in the Expression, Purification, and Characterization of Recombinant Collagen.Bioengineering (Basel, Switzerland) · 2026Review
- A Comprehensive Review on Steviol Glycosides: Sources, Properties, Bioactivities, Sensory-Functional Enhancement and Bioproduction Strategies.Plants (Basel, Switzerland) · 2026Review
- Signaling pathways contributing to the transcriptional response to alkalinization in Komagataella phaffii: role of the transcription factors Crz1 and Rim101.Scientific reports · 2025Article
- Expression and purification of a broad-spectrum human protease inhibitor inBiochemistry and biophysics reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The methylotrophic yeast Pichia pastoris is garnering interest as a chassis cell factory for the manufacture of recombinant proteins because it effectively satisfies the requirements of both laboratory and industrial set up. The optimisation of P. pastoris cultivation is still necessary due to strain- and product-specific problems such as promoter strength, methanol utilisation type, and culturing conditions to realize the high yields of heterologous protein(s) of interest. Techniques integrating genetic and process engineering have been used to overcome these problems. Insight into the Pichia as an expression system utilizing MUT pathway and the development of methanol free systems are highlighted in this systematic review. Recent developments in the improved production of proteins in P. pastoris by (i) diverse genetic engineering such as codon optimization and gene dosage; (ii) cultivating tactics including co-expression of chaperones; (iii) advances in the use of the 2A peptide system, and (iv) CRISPR/Cas technologies are widely discussed. We believe that by combining these strategies, P. pastoris will become a formidable platform for the production of high value therapeutic proteins.
Indexed as
Identifiers
37400712What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.